RxDoctor Payments Data

Antonio Crespo, MD

Infectious Disease · Orlando, FLNPI 1033185392

Payments from drug & device makers

$1,336in general payments, 2019–2025

Across 27 payments — averaging $49.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ferring Pharmaceuticals Inc.$439
  • Viiv Healthcare Company$339
  • Astellas Pharma US Inc$162
  • Gilead$137
  • Paratek Pharmaceuticals, Inc.$110
  • Insmed, Inc.$80
  • plus $69 from 4 others

What the payments were for

  • Food & beverage$1,09482%
  • Education$24218%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,336 in reported general payments places this provider in the 55th percentile of 669 infectious disease providers in Florida.

See all infectious disease providers in Florida

Medicare billing

Part B allowed, 2024
$77,608
Medicare patients
248
Services billed
633

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala141$570,536
CabenuvaCabotegravir/Rilpivirine15$96,755
DovatoDolutegravir Sodium/Lamivudine29$94,440
TriumeqAbacavir/Dolutegravir/Lamivudi13$48,433
TivicayDolutegravir Sodium20$47,126
JulucaDolutegravir/Rilpivirine13$41,342
IsentressRaltegravir Potassium13$27,998
Daptomycin50$24,061
EdurantRilpivirine Hcl13$17,792
Vancomycin Hcl42$5,135
CeftriaxoneCeftriaxone Sodium55$5,027
Cefepime Hcl18$2,390
Lamivudine14$1,165
Cefazolin Sodium13$788
Doxycycline Hyclate19$473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$137$570,536141 claims
Viiv Healthcare CompanyCabenuva, Dovato, Triumeq, Tivicay, Juluca$339$328,09590 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 669 infectious disease providers in Florida.

Other infectious disease in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →